Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27553730 | 0.81 | USP2 (0.58) | ALDH1A1NPC1USP2HPGDALOX15 | |
| SCHEMBL7735928 | 0.80 | ALDH1A1 (0.71) | ALDH1A1NPC1USP2HPGDMAPT | |
| Bromide SCHEMBL7340063 | 0.79 | USP2 (0.56) | ALDH1A1NPC1USP2HPGDALOX15 | |
| Hydrochloric Acid SCHEMBL6538607 | 0.78 | HTR2A (0.55) | ALDH1A1NPC1USP2S1PR1ITGB3 | |
| SCHEMBL6539303 | 0.77 | L3MBTL3 (0.48) | ALDH1A1USP2MAPTSMN1; SMN2 | |
| SCHEMBL1387857 | 0.77 | ALDH1A1 (0.43) | ALDH1A1NPC1USP2HPGDGSK3B | |
| SCHEMBL6301694 | 0.76 | MAPT (0.72) | ALDH1A1USP2S1PR1ALOX15MAPT | |
| SCHEMBL23816922 | 0.75 | SLC18A3 (0.60) | ALDH1A1 | |
| SCHEMBL13723844 | 0.75 | MAPT (0.59) | ALDH1A1NPC1USP2S1PR1ITGB3 | |
| SCHEMBL20271722 | 0.75 | SMN1; SMN2 (0.68) | ALDH1A1S1PR1MAPTGFERSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | ENGASE, NEU1, NEU2 | ALDH1A1 867/4885NPC1 1547/4885USP2 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.